Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more.
Unlock these with Subscription
The View From India Looking at World Affairs from the Indian perspective.
First Day First Show News and reviews from the world of cinema and streaming.
Today's Cache Your download of the top 5 technology stories of the day.
Science For All The weekly newsletter from science writers takes the jargon out of science and puts the fun in!
Data Point Decoding the headlines with facts, figures, and numbers
THEdge At the cutting edge of education and careers
Health Matters Ramya Kannan writes to you on getting to good health, and staying there
Gender Agenda Stories from beyond the binary.
The Hindu On Books Books of the week, reviews, excerpts, new titles and features.
Updated - September 04, 2026 03:11 pm IST - HYDERABAD
Drugmaker Cipla, through subsidiary Invagen Pharmaceuticals, has entered into a partnership with China’s Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab) in the U.S.
Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialisation of the asset by leveraging its strong commercial presence in the defined territory, the company said on Thursday (September 3).
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio, said Achin Gupta, MD and and Global CEO of Cipla.
“With our established commercial capabilities, we are well-positioned to successfully launch QL2107, subject to regulatory approval, and help ensure it reaches patients in need while lowering the cost of treatment,” Cipla North America CEO Marc Falkin said.
Qilu Pharmaceutical General Manager Hanchang Zhang said “by combining our R&D and manufacturing strengths with Cipla’s U.S. commercial expertise, we aim to bring a high-quality, affordable pembrolizumab biosimilar to U.S. patients.”
business (general) / pharmaceutical / health / cancer / health treatment
Terms & conditions | Institutional Subscriber
Comments have to be in English, and in full sentences.
They cannot be abusive or personal.
Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform.
If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles.
If you do not have an account please register and login to post comments.
Users can access their older comments by logging into their accounts on Vuukle.
Full detailed coverage is shown on the council website above. Source attribution: The Hindu – Business.
Back to all council news
